Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  letrozole
Find trials that include:  Any drugs shown
Results 1-25 of 29 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Continuous or Intermittent Letrozole in Treating Postmenopausal Patients With Hormone Receptor-Positive Early Stage Breast Cancer
Phase: Phase III
Type: Prevention
Age: Postmenopausal
Trial IDs: 10-356, NCI-2011-00739, IBCSG-35-07, BIG-1-07-SOLE, EUDRACT-2007-001370-88, EU-20772, NCT00553410
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011A2301, NCI-2014-00491, 2013-003084-61, NCT01958021
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 59
Trial IDs: CLEE011E2301, NCI-2014-02508, NCT02278120
Dovitinib Lactate in Combination With Anastrozole, Exemestane, or Letrozole in Treating Patients With Hormone-Receptor Positive Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-535, NCI-2013-00749, NCT01484041
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Phase: Phase II, Phase I
Type: Treatment
Age: not specified
Trial IDs: TED12414, NCI-2012-02198, 2011-006140-78, U1111-1124-1403, NCT01587040
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, NCT01872260
Control or Extended Lapatinib Ditosylate and Trastuzumab With or Without Goserelin Acetate or Letrozole in Treating Patients With HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 023, NCI-2012-01766, H-25846, NCT00999804
Letrozole in Treating Postmenopausal Women with Ductal Carcinoma in Situ
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: CALGB 40903, NCI-2011-03452, CDR0000701992, NCT01439711
Pazopanib Hydrochloride and Anastrozole or Letrozole in Treating Patients With Advanced Hormone-Resistant Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117513, NCI-2012-00494, NCT01466972
Everolimus, Letrozole, and Metformin Hydrochloride in Treating Patients with Advanced or Recurrent Endometrial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0543, NCI-2013-00960, RAD001CUS195T, NCT01797523
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
Palbociclib Isethionate and Endocrine Therapy in Treating Patients with Hormone Receptor-Positive Stage II-III Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-559, NCI-2014-00937, NCT02040857
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GOG-3007, NCI-2015-00993, CRAD001CUS236T, NCT02228681
Aromatase Inhibitors with Everolimus before Surgery in Treating Postmenopausal Patients with Hormone Receptor Positive, HER2 Negative, Stage II-IIIC Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CRAD001JUS228T, NCI-2014-02280, 1405013982, NCT02236572
A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GO28888, NCI-2014-02653, NCT02273973
BYL719 and Letrozole With or Without Trastuzumab in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 12101, NCI-2013-00102, CBYL719XUS03T, SU2C B07, NCT01791478
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15252, NCI-2014-01032, I3Y-MC-JPBH, NCT02057133
Start Over